Third Quarter 2026
Filed Nov 4, 2026Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
MRD revenue increased 28%, clonoSEQ test volume increased 46%, and the company reported adjusted EBITDA of $14.3 million and free cash flow of $7.7 million. However, total revenue decreased 11%, Immune Medicine revenue decreased 70%, and GAAP net income declined to $2.8 million from $9.5 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30GAAP | $83.90M | – | 11% decrease |
| Revenue excluding revenue recognized under the Genentech Agreement, three months ended September 30other | $83.9M | – | 39% increase |
| Revenue, nine months ended September 30GAAP | $226.3M | – | – |
| Cost of revenue, three months ended September 30GAAP | $19.93M | – | – |
| Research and development expense, three months ended September 30GAAP | $18.64M | – | – |
| Sales and marketing expense, three months ended September 30GAAP | $26.90M | – | – |
| General and administrative expense, three months ended September 30GAAP | $18.46M | – | – |
| Amortization of intangible assets, three months ended September 30GAAP | $428K | – | – |
| Total operating expenses, three months ended September 30GAAP | $84.36M | – | increase of 1% |
| Income from operations, three months ended September 30GAAP | $10.29M | – | – |
| Loss from operations, three months ended September 30GAAP | −$457K | – | – |
| Interest and other income, net, three months ended September 30GAAP | $3.77M | – | – |
| Interest expense, three months ended September 30GAAP | −$503K | – | – |
| Net income, three months ended September 30GAAP | $2.81M | – | – |
| Net income attributable to Adaptive Biotechnologies Corporation, three months ended September 30GAAP | $2.88M | – | – |
| Net income per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted, three months ended September 30GAAP | $0.02 | – | – |
| Adjusted EBITDA, three months ended September 30non-GAAP | $14.35M | – | – |
| Adjusted EBITDA excluding revenue generated from the Genentech Agreement, three months ended September 30, 2025non-GAAP | a loss of $5.8 million | – | – |
| Free cash flow, third quarter of 2026other | $7.7M | – | – |
| Revenue, nine months ended September 30GAAP | $226.3M | – | – |
| Total operating expenses, nine months ended September 30GAAP | $261.8M | – | – |
| Loss from operations, nine months ended September 30GAAP | −$35.43M | – | – |
| Net loss, nine months ended September 30GAAP | −$57.15M | – | – |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted, nine months ended September 30GAAP | $(0.36) | – | – |
| Adjusted EBITDA, nine months ended September 30non-GAAP | $11.15M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| MRDDelivered 39,587 clonoSEQ tests in the third quarter of 2026, an increase of 46% versus the third quarter of 2025. | $72.56M | – | 28% increase |
| Immune MedicineExcluding revenue generated from the Genentech Agreement, Immune Medicine revenue for the quarter ended September 30, 2026 increased 229% from the third quarter in the prior year. | $11.34M | – | 70% decrease |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Revenue$276 million to $286 million
- Operating expensesapproximately $350 million
- NoteMRD revenue guidance represents annual growth of 30% to 35%.
- NoteNo revenue guidance is provided for the Immune Medicine business.
What drove it
- MRD revenue was $72.6 million for the quarter and increased 28% from the third quarter in the prior year.
- clonoSEQ test volume was 39,587 tests, an increase of 46% versus the third quarter of 2025.
- NCCN Guidelines established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance.
- The International Myeloma Working Group introduced the first definition of cure for multiple myeloma, requiring a five-year treatment-free period with sustained MRD negativity assessed at a sensitivity of one myeloma cell among one million cells.
- The company submitted a technical assessment to MolDX seeking an additional Medicare bundle for maintenance testing in multiple myeloma.
- The company recognized revenue from successful data delivery under its target discovery agreement and is progressing with the Immune Medicine separation process.
Concerns
- Total revenue decreased 11% from the third quarter in the prior year because the quarter ended September 30, 2026 did not generate revenue under the Genentech Agreement.
- Immune Medicine revenue decreased 70% from the third quarter in the prior year.
- GAAP net income was $2.8 million, compared to $9.5 million for the same period in 2025.
- Adjusted EBITDA was $14.3 million, compared to $28.0 million for the third quarter of the prior year.
- No revenue guidance is provided for the Immune Medicine business.
What to watch
- MRD revenue performance against the updated full year 2026 range of $276 million to $286 million.
- clonoSEQ test-volume growth and the potential outcome of the MolDX technical assessment for an additional Medicare maintenance-testing bundle.
- Implementation of annual maintenance testing in the NCCN MRD assessment framework for multiple myeloma.
- Progress of the Immune Medicine separation process and revenue from target discovery agreements.
- Total company operating expenses relative to approximately $350 million for full year 2026.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities was $400.2 million as of September 30, 2026, inclusive of $13.8 million of cash and cash equivalents held by Digital Biotechnologies, Inc.
- Cash and cash equivalents were $75,615 (in thousands) as of September 30, 2026, compared to $70,495 (in thousands) as of December 31, 2025.
- Short-term marketable securities were $223,339 (in thousands) as of September 30, 2026, compared to $156,485 (in thousands) as of December 31, 2025.
- Long-term marketable securities were $101,227 (in thousands) as of September 30, 2026, compared to $13,234 (in thousands) as of December 31, 2025.
- Convertible senior notes, net were $335,379 (in thousands) as of September 30, 2026, compared to $0 (in thousands) as of December 31, 2025.
- Revenue interest liability, net, less current portion was $0 (in thousands) as of September 30, 2026, compared to $126,566 (in thousands) as of December 31, 2025.
- Free cash flow was $7.7 million in the third quarter of 2026.
Analysis
Adaptive reported third-quarter revenue of $83.9 million, an 11% decrease from the third quarter in the prior year, but stated that revenue excluding the Genentech Agreement increased 39%. The reported decline reflects the absence of Genentech Agreement revenue in the current quarter. MRD was the clear growth engine, with revenue of $72.6 million, up 28%, and 39,587 clonoSEQ tests delivered, up 46% versus the third quarter of 2025. Immune Medicine revenue was $11.3 million and decreased 70%, although the company stated that revenue excluding the Genentech Agreement increased 229%.
Profitability improved on the reported operating profile despite the lower total revenue base. The company reported adjusted EBITDA of $14.3 million and free cash flow of $7.7 million, which it described as total company profitability. GAAP net income was $2.8 million, compared with $9.5 million in the prior-year quarter, while adjusted EBITDA was below the prior-year $28.0 million. Total operating expenses were $84.4 million, up 1%, with research and development expense declining to $18.6 million while sales and marketing and general and administrative expense increased to $26.9 million and $18.5 million, respectively.
The nine-month results show revenue of $226.3 million compared with $205.3 million in the prior-year period, while the GAAP net loss increased to $57.2 million from $45.9 million. The nine-month loss included a $23.7 million loss on revenue interest liability extinguishment. Nine-month adjusted EBITDA was $11.2 million, compared with $8.0 million in the prior-year period. The balance sheet reported $400.2 million of cash, cash equivalents and marketable securities as of September 30, 2026, while convertible senior notes, net were $335.4 million and the long-term revenue interest liability was eliminated.
Management raised full-year 2026 MRD revenue guidance to $276 million to $286 million from $268 million to $278 million, representing stated annual growth of 30% to 35%. Full-year total company operating-expense guidance, including cost of revenue, was updated to approximately $350 million from a prior range of $350 million to $355 million. The release provides no revenue guidance for Immune Medicine, leaving the pace and composition of that business a key area of attention alongside MRD testing volume, reimbursement expansion efforts and the planned Immune Medicine separation process.
Management, verbatim
Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue.
Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies
This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.
Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies
Not in the filing
stated, not guessed- Gross margin and gross-margin guidance
- Operating cash flow
- Free cash flow reconciliation and prior-period free cash flow
- Income tax expense or benefit and tax rate
- Capital return activity, including share repurchases and dividends
- Prior-quarter comparisons for reported financial metrics
- Revenue guidance for the Immune Medicine business
- A separate previous-release outlook section for formal actual-versus-prior-guidance comparisons
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.